Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Inclusion Criteria: * Written informed consent to participate in this extension study, signed prior to the performance of any study procedures * Receipt of 12 weeks of investigational product with completion of the procedures in Study ALT-801-105 * Women who are not pregnant or breastfeeding Exclusion Criteria: * Meets any of the exclusion criteria in Study ALT-801-105 at the time of study entry * Development of any of the following conditions at any time during Study ALT-801-105: 1. Type 1 DM and/or insulin-dependent type 2 diabetes mellitus (T2DM), or uncontrolled T2DM requiring rescue therapy in study ALT-801-105 2. History of pancreatitis or hypersensitivity reaction to GLP-1 analogues